Home › Trials › NCT06566586

Evaluating TQB3702 tablets with immunochemotherapy for B-cell lymphoma treatment

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Phase 2 Interventional Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06566586

This study is testing if TQB3702 tablets can work better with immunochemotherapy to help people with relapsed or hard-to-treat B-cell lymphoma.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment80 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd. Industry-sponsored
Locations30 sites (Beijing, Beijing Municipality and 29 other locations)
Trial IDNCT06566586 on ClinicalTrials.gov

What this trial studies

This clinical study aims to assess the efficacy and safety of TQB3702 tablets when combined with immunochemotherapy in patients diagnosed with B-cell lymphoma. Participants will receive the TQB3702 treatment alongside a standard chemotherapy regimen. The study will focus on patients with relapsed or refractory forms of B-cell lymphoma, ensuring that they meet specific eligibility criteria, including age and health status. The goal is to determine whether this combination therapy can improve treatment outcomes for these patients.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 to 75 with histologically confirmed relapsed or refractory B-cell lymphoma who have previously undergone systemic therapy.

Not a fit: Patients with non-B-cell lymphoma or those who do not meet the specified health and treatment criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients suffering from B-cell lymphoma.

How similar studies have performed: Other studies have shown promise in combining immunotherapy with chemotherapy for lymphoma treatment, suggesting potential success for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* The subjects voluntarily joined the study, signed the informed consent, and the compliance was good;
* Age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; Eastern cooperative oncology group (ECOG) score: 0-2; Expected survival of more than 3 months;
* Histologically confirmed B-cell lymphomas of the following types that meet the 2022 World Health Organization (WHO) diagnostic criteria:

  1. Relapsed/refractory indolent B-cell lymphoma
  2. Diffuse large B cell lymphoma（DLBCL）
* Previous treatment: Relapsed/refractory inert B-cell lymphoma: have received at least one previous line of systemic standard therapy
* Have at least one measurable lesion.
* The main organs function well.
* Female subjects of reproductive age should agree to use contraception (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the end of the study; Have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; Male subjects should agree to use avoidance during the study period and for 6 months after the end of the study period.

Exclusion Criteria:

* Have had or are currently suffering from other malignant tumors within 3 years prior to the first medication.
* Known or suspected central nervous system (CNS) aggression.
* Relapsed/refractory inert B-cell lymphoma: previous allogeneic hematopoietic stem cell transplantation, or autologous hematopoietic stem cell transplantation within 3 months before the first treatment;
* Recurrent/refractory indolent B-cell lymphoma: toxic reactions that do not return to ≤ National Cancer Institute standard for common toxic reactions (NCI-CTC) AE Grade 1 due to any previous treatment, excluding hair loss and fatigue;
* Have multiple factors that affect oral drug absorption (such as inability to swallow, chronic diarrhea, and intestinal obstruction);
* Received major surgical treatment or significant traumatic injury within 28 days before the start of study treatment;
* Hyperkinetic/venous thrombosis events occurred within 6 months before the first medication;
* Have a history of psychotropic drug abuse and can not quit or have mental disorders;
* Subjects with any severe and/or uncontrolled disease;
* Received live vaccine or messenger ribonucleic acid (mRNA) vaccine within 4 weeks before the first dose, or planned to receive live vaccine or mRNA vaccine during the study;
* Participated in clinical trials of other antitumor drugs within 4 weeks before the first medication;
* Subjects who, in the judgment of the investigator, have concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are not suitable for enrollment for other reasons.

Where this trial is running

Beijing, Beijing Municipality and 29 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions B-cell Lymphoma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.